Fabino Life Sciences (BOM:543444) Cash-to-Debt : 0.93 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Fabino Life Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Fabino Life Sciences's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.93.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Fabino Life Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Fabino Life Sciences's Cash-to-Debt or its related term are showing as below:

BOM:543444' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 0.6 Max: 12.67
Current: 0.93

During the past 5 years, Fabino Life Sciences's highest Cash to Debt Ratio was 12.67. The lowest was 0.04. And the median was 0.60.

BOM:543444's Cash-to-Debt is ranked worse than
50.14% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs BOM:543444: 0.93

Fabino Life Sciences Cash-to-Debt Historical Data

The historical data trend for Fabino Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Fabino Life Sciences Cash-to-Debt Chart

Fabino Life Sciences Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

0.04

0.16

0.21

12.67

0.60

Fabino Life Sciences Semi-Annual Data
	Mar19	Mar20	Mar21	Mar22	Sep22	Mar23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial			0.21	12.67	6.23	0.60	0.93

Competitive Comparison of Fabino Life Sciences's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Fabino Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fabino Life Sciences's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fabino Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Fabino Life Sciences's Cash-to-Debt falls into.

Fabino Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Fabino Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.425	/	(0	+	4.061)
	=	0.60

Fabino Life Sciences's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	10.173	/	(0	+	10.978)
	=	0.93

Fabino Life Sciences (BOM:543444) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Fabino Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Fabino Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Fabino Life Sciences (BOM:543444) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fabino Life Sciences Ltd (BOM:543444) » Definitions » Cash-to-Debt

Traded in Other Exchanges

N/A

Address

Murthal Road,, Shubham Garden, Jeevan Vihar Extension Near, Sonipat, HR, IND, 131001

Website

https://www.fabinolife.com

Fabino Life Sciences Ltd is a pharmaceutical company. It is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness-focused consumer products. It offers a wide range of allopathic, Food and wellness, Veterinary, Multi-vitamin and herbal products. The company currently supplies in Haryana, Delhi, parts of Punjab, Himachal Pradesh, Eastern Uttar Pradesh, Orissa, and Jharkhand, and parts of West Bengal, Andhra Pradesh, and Nepal.

Fabino Life Sciences (BOM:543444) Headlines

No Headlines